Following a disappointing performance from the company’s CAR-T candidate in an early-stage cancer trial, BioNTech is winding down cell therapy manufacturing at its inaugural U.S. plant. BioNTech will ...
BioNTech has already been tinkering with its manufacturing processes in the run up to CAR-T BNT211 entering pivotal trials. Now, the German biotech has brought British company Autolus Therapeutics on ...
German Federal Cartel Office clearance obtained for the planned BioNTech - CureVac transaction announced on June 12, 2025, marking an important step toward the expected closing later this year Offer ...
As BioNTech progresses with its goal to grow into a “fully integrated immunotherapy powerhouse,” the German biotech is eying a 2025 regulatory filing for what could become its first approved cancer ...
Amid growing financial concerns and US vaccine hesitancy, the German company will close its mRNA site in Southeast Asia.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results